Checkpoint Inhibitor

Sticker price of blockbuster drug needs to be cut by 46% to reach willingness-to-pay thresholds

Findings suggest possible benefits of ICI therapy on field cancerization, researchers say

Meta-analysis shows better PFS, OS with RT-first approach, but issue requires more study

One of your patients could be eligible for a new clinical trial for fibroids or gynecologic cancer.

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or no PD-L1 expressors doesn't outweigh the risks.

Neoadjuvant immunotherapy yielded similar survival and surgical outcomes to upfront surgery in high-risk HCC and could broaden surgical options for traditionally unresectable cases.

Early recurrence after anti-PD-1/L1 likely to benefit more from anti-CTLA-4, targeted agents

Almost 50% improvement in median survival, but against a suboptimal control regimen

Dostarlimab and pembrolizumab regimens should be incorporated into practice 'as of yesterday'

A new FDA-approved treatment for melanoma has hit the market with a high price, and clinicians are working with insurers to determine out-of-pocket costs for patients.

Interim findings from the ongoing AMBASSADOR trial revealed a significant DFS benefit with adjuvant pembrolizumab but no overall survival benefit at this point.

Combination improved PFS versus more hormonal therapy, but control arm questioned

Johns Hopkins researchers have identified minuscule particles that supercharge therapeutic cancer vaccines, which train the immune system to attack tumors. These new lipid nanoparticles—tiny structures made of fat—not only stimulate a two-pronged immune system response that enhances the body's ability to fight cancer but also make vaccines more effective in targeting tumors.

Response rates of 14% alone and 18% in combination with checkpoint inhibitor

Adding pembrolizumab to chemotherapy had significant benefits in patients with locally advanced unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Antibody-drug conjugates in particular may present clinicians with less familiar side effects

Suspect perineural recurrence of cutaneous squamous cell carcinoma, experts urge

Strategies involving immunotherapy, induction chemo move the needle for first time in decades

/PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC), the world's leading member-driven organization dedicated to improving patient outcomes by...

The newest frontier in immunotherapy may soon be settled clinical territory